EHA: European Hematology Association

Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.

Patients with relapsed/refractory (R/R) multiple myeloma and lower socioeconomic status reported significantly worse quality of life and a higher burden of symptoms, according to Francesco Sparano, MSc, of the GIMEMA Foundation.

Our knowledge of the effects of space and low gravity on blood cells, clotting, and anemia continues to expand, but further research is needed as commercial spaceflights are poised to grow in popularity.

Early results from the phase 1 SANRECO trial suggest that divesiran is safe and well tolerated, and may reduce the need for phlebotomy in patients with polycythemia vera by increasing hepcidin levels and improving iron regulation, according to lead investigator Marina Kremyanskaya, MD, PhD.

A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.

Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.

Sundar Jagannath, MBBS, highlights long-term follow-up data from the phase 1b/2 CARTITUDE-1 trial, showing durable responses and potential cures with ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, demonstrating efficacy with no new safety signals.

An artificial intelligence (AI)-driven machine learning model was refined and validated internationally to accurately classify acute leukemia subtypes from routine laboratory data, according to Merlin Engelke, MS, offering a potential tool for improving diagnosis worldwide.

In this clip, Adela Perolla, MD, PhD, discusses the urgent need to address and destigmatize burnout in hematology, especially among early-career professionals, by promoting self-awareness, work-life balance, and peer support.

Burnout is rising sharply in hematology due to emotional strain, long hours, and high patient demands, according to Adela Perolla, MD, PhD, impacting both physician well-being and patient care.

Ola Landgren, MD, PhD, shares ADVANCE trial results, which show that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (DKRd) improves outcomes in newly diagnosed multiple myeloma.

Ola Landgren, MD, PhD, lead investigator of the ADVANCE clinical trial, outlines the study’s goal of advancing modern, minimal residual disease–guided treatment approaches.

Both monotherapy and combination therapy containing epcoritamab had high response rates and survival benefits when compared with usual care.

Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) in transplant-ineligible or deferred newly diagnosed multiple myeloma.

Ahead of the 30th European Hematology Association (EHA) Congress in Milan, Ola Landgren, MD, PhD, shares what he is most looking forward to and reflects on key advancements and ongoing challenges in hematology.

The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.

Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow was showcased.

Presentations at the European Hematology Association (EHA) 2024 Congress were encouraging for their data on innovations within the hematology/oncology space that are reshaping treatment outcomes.

In part 1 of our interview with Anna Sureda, MD, PhD, president of the European Group for Blood and Marrow Transplantation, she summarized the current treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular lymphoma (FL).

Ryan Jacobs, MD, lymphoma division director at Atrium Health Levine Cancer Institute, explains the design and objectives of the phase 2 CAPTIVATE study comparing ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL).

In this interview from our coverage of the European Hematology Association 2024 Congress, we spoke with Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, executive vice president and chief medical officer of the CLL Society and himself a survivor of chronic lymphocytic leukemia (CLL), to discuss treatment advancements and the importance of addressing both unmet needs and patient treatment preferences.

Ibrahim Aldoss, MD, of City of Hope, discusses promising phase 2 results of the WU-CART-007 trial, demonstrating high efficacy manageable safety for W-T7 in relapsed/refractory T-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL).

Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, discusses the evolving treatment landscape for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma.

In the final part of our interview with Joseph Mikhael, MD, MEd, FRCPC, FACP, he addresses how patients who experience an early relapse of their multiple myeloma are predisposed to worse outcomes.

In part 2 of our interview with Suzanne Lentzsch, MD, PhD, Columbia University's College of Physicians and Surgeon, she touches on potential new therapies, important clinical considerations, and treatment challenge for relapsed/refractory multiple myeloma.

In this interview from our coverage of the European Hematology Association 2024 Congress, Joseph Mikhael, MD, MEd, FRCPC, FACP, International Myeloma Foundation, discusses the complex principles that underlie treating multiple myeloma (MM) in the US.

Experts share their biggest takeaways from the European Hematology Association (EHA) 2024 Congress.

Suzanne Lentzsch, MD, PhD, of Columbia University, presented promising results of linvoseltamab for treating relapsed/refractory multiple myeloma (RRMM) at the European Hematology Association 2024 Congress.

Enthusiasm abounded at the recent European Hematology Association 2024 Congress about whether European regulators will begin to consider minimal residual disease (MRD) as an end point.